Use

CCAAT/enhancer‑binding protein alpha (CEBPA) mutations are detected in about 7‑15% of patients with acute myeloid leukemia (AML). Double (biallelic) mutations are associated with good prognosis in patients with intermediate‑risk and normal cytogenetics who do not have FLT3‑ITD mutations. This test aids in assessing the prognosis of newly diagnosed AML patients with normal or intermediate‑risk cytogenetics.